Audit 12 of 80
@drtrevorbachmeyer
Verdict summary:
The foundational mechanistic claims (CJC-1295 as a signaling peptide, half-life profiles, and Ipamorelin's selectivity) are supported by pharmacology literature and align with known GH secretagogue physiology.
- Verdict:
- ⚠️ Overstated
- Posted:
- 9 months ago
What the evidence shows:
- However, the specific quantitative claims — particularly the 2x–10x IGF-1 fold-change trajectory and the assertion that CJC-1295 + Ipamorelin 'restores the GH axis to age 25' — exceed what is explicitly documented in published human trials.
- The Teichman et al. (2006) Phase 2 study confirms CJC-1295 DAC elevates IGF-1 sustainably, validating the direction; but the granular quantitative claims represent creator interpretation rather than direct study findings.

Conclusion:
The combination claim lacks cited peer-reviewed support and overstates the evidence base for 'youthful restoration.'
Full audit history for @drtrevorbachmeyer









